List view / Grid view
Researchers at the US National Heart, Lung, and Blood Institute have discovered new insights about lymphangioleiomyomatosis, a rare lung disease that affects about one in 200,000 Americans.
Researchers have made a respiratory model of COVID-19, made from patient-derived stem cells, to understand how the virus affects respiration and which could be used to test possible drugs.
Using chemical genetic screening and pre-clinical model studies, researchers have discovered that inducing ubiquitin-mediated degradation of mutant EZH2 could provide a more effective treatment strategy for haematologic malignancies.
The length of time that drug molecules attach to their target protein varies greatly and impacts the protein’s behaviour and drug efficacy. In a new study, scientists in Finland have identified some causal factors for this variance, with the hope it will bring clarity for drug developers.
Scientists in Japan have developed a credible heart cell model for arrhythmogenic cardiomyopathy and observed a positive response in the condition using PKP2 gene therapy.
Benefits and key considerations of using human iPSC-derived disease models in drug discovery.
During investigations into the tropical disease Buruli ulcer, researchers have instead identified a promising new avenue for potential treatments for multiple myeloma.
A research team based at Skoltech in Russia has developed an artificial intelligence-driven solution for highly accurate detection of efficacious binding sites to expedite drug discovery.
Accelerate your drug discovery workflows efficiently and cost-effectively with lab automation solutions from Beckman Coulter Life Sciences.
Read about the latest addition Invitrogen™ TrueCut™ HiFi Cas9 Protein to support your application and research goals.
The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.
The new high-throughput screening method identified nine lead molecules for rhodopsin dimerisation that may lead to next-generation medicines.
Scientists develop organoid models of neuroendocrine prostate cancer to study EZH2 inhibitors and reveal a potential new target.
The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.
A new study claims that future COVID-19 vaccines should activate T cells to attack infected cells expressing replication proteins.
